Larotrectinib Is Promising for Pediatric TRK Fusion-Positive CNS TumorsOPACCNov 28, 20241 min readLarotrectinib led to rapid/durable responses and high disease control rates in children with TRK fusion-position central nervous system cancers. Read more: https://www.oncnursingnews.com/view/larotrectinib-is-promising-for-pediatric-trk-fusion-positive-cns-tumors
Comments